/
Oncology
Lymphoma, B-Cell
17
Pipeline Programs↗
6
Active Trials↗
11
Companies Involved↗
Lymphoma, B-Cell is an emerging landscape with 17 programs across 11 companies. The most active players are Bristol-Myers Squibb, Bantam Pharmaceuticals.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical
No programs
Phase 117
Phase 2
No programs
Phase 3
No programs
Approved
No programs
Analysis
Modality Breakdown
76%
Small molecule
13 of 17 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 17 classified programs, each share of the total. Modality classified for 100% of 17 pipeline programs.
Analysis
Trial Status
7
clinical trials
Recruiting4 · 57%
Active, not recruiting2 · 29%
Withdrawn1 · 14%
Clinical Trials
Trial Activity
7 trials
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)